Youki Ueda

Youki Ueda

Auto-generated profile, based on publicly available information

Youki Ueda

Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2025 in Nature
Verified
Journal Article
Open access
PDF file
HIHideki Ikeda
Hideki Ikeda
KKKatsushige Kawase
Katsushige Kawase
TNTatsuya Nishi
Tatsuya Nishi
TWTomofumi Watanabe
Tomofumi Watanabe
KTKeizo Takenaga
Keizo Takenaga
YTYosuke Togashi
Yosuke Togashi
Cancer cells in the tumour microenvironment use various mechanisms to evade the immune system, particularly T cell attack1. For example, metabolic reprogramming in the tumour microenvironment and mitochondrial dysfunction in tumour-infiltrating lymphocytes (TILs) impair antitumour immune responses2,3,4. However, detailed mechanisms of such processes remain unclear. Here we analyse clinical specimens and identify mitochondrial DNA (mtDNA) mutations in TILs that are shared with cancer cells. Moreover, mitochondria with mtDNA mutations from cancer cells are able to transfer to TILs. Typically, mitochondria in TILs readily undergo mitophagy through reactive oxygen species. However, mitochondria transferred from cancer cells do not undergo mitophagy, which we find is due to mitophagy-inhibitory molecules. These molecules attach to mitochondria and together are transferred to TILs, which results in homoplasmic replacement. T cells that acquire mtDNA mutations from cancer cells exhibit metabolic abnormalities and senescence, with defects in effector functions and memory formation. This in turn leads to impaired antitumour immunity both in vitro and in vivo. Accordingly, the presence of an mtDNA mutation in tumour tissue is a poor prognostic factor for immune checkpoint inhibitors in patients with melanoma or non-small-cell lung cancer. These findings reveal a previously unknown mechanism of cancer immune evasion through mitochondrial transfer and can contribute to the development of future cancer immunotherapies.

16 October 2015 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
HDHiromichi Dansako
Hiromichi Dansako
YUYouki Ueda
Youki Ueda
NONobuaki Okumura
Nobuaki Okumura
SSShinya Satoh
Shinya Satoh
MSMasaya Sugiyama
Masaya Sugiyama
NKNobuyuki Kato
Nobuyuki Kato
During viral replication, the innate immune response is induced through the recognition of viral replication intermediates by host factor(s). One of these host factors, cyclic GMP‐AMP synthetase (cGAS), was recently reported to be involved in the recognition of viral DNA derived from DNA viruses. However, it is uncertain whether cGAS is involved in the recognition of hepatitis B virus (HBV), which is a hepatotropic DNA virus. In the present study, we demonstrated that HBV genome‐derived double‐stranded DNA induced the innate immune response through cGAS and its adaptor protein, stimulator of interferon genes (STING), in human hepatoma Li23 cells expressing high levels of cGAS. In addition, we demonstrated that HBV infection induced ISG56 through the cGAS–STING signaling pathway. This signaling pathway also showed an antiviral response towards HBV through the suppression of viral assembly. From these results, we conclude that the cGAS–STING signaling pathway is required for not only the innate immune response against HBV but also the suppression of HBV assembly. The cGAS–STING signaling pathway may thus be a novel target for anti‐HBV strategies.

1 May 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YUYouki Ueda
Youki Ueda
KMKyoko Mori
Kyoko Mori
SSShinya Satoh
Shinya Satoh
HDHiromichi Dansako
Hiromichi Dansako
MIMasanori Ikeda
Masanori Ikeda
NKNobuyuki Kato
Nobuyuki Kato

1 October 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HIHirotaka Imai
Hirotaka Imai
HDHiromichi Dansako
Hiromichi Dansako
YUYouki Ueda
Youki Ueda
SSShinya Satoh
Shinya Satoh
NKNobuyuki Kato
Nobuyuki Kato

5 November 2018 in FASEB BioAdvances
Verified
Journal Article
Open access
PDF file
HDHiromichi Dansako
Hiromichi Dansako
HIHirotaka Imai
Hirotaka Imai
YUYouki Ueda
Youki Ueda
SSShinya Satoh
Shinya Satoh
KSKunitada Shimotohno
Kunitada Shimotohno
NKNobuyuki Kato
Nobuyuki Kato
Hepatitis B virus (HBV) is a hepatotropic DNA virus causing hepatic diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. To study HBV, human hepatoma HepG2 cells are currently used as an HBV infectious cell culture model worldwide. HepG2 cells exhibit susceptibility to HBV by exogenously expressing sodium taurocholate cotransporting polypeptide (NTCP). We herein demonstrated that human immortalized hepatocyte NKNT‐3 cells exhibited susceptibility to HBV by exogenously expressing NTCP (NKNT‐3/NTCP cells). By comparing cyclic GMP‐AMP synthetase (cGAS)‐stimulator of interferon genes (STING) signaling pathway in several NKNT‐3/NTCP cell‐derived cell clones, we found that STING was highly expressed in cell clones exhibiting resistance but not susceptibility to HBV. High‐level expression of STING was implicated in HBV‐triggered induction of type III IFN and a pro‐inflammatory cytokine, IL‐6. In contrast, RNAi‐mediated knockdown of STING inhibited type III IFN induction and restored the levels of HBV total transcript in an HBV‐infected cell clone exhibiting resistance to HBV. These results suggest that STING regulates susceptibility to HBV by its expression levels. STING may thus be a novel target for anti‐HBV strategies.

13 January 2025 in Cancer Research
Verified
Journal Article
Closed access
TNToshifumi Ninomiya
Toshifumi Ninomiya
NKNaoya Kemmotsu
Naoya Kemmotsu
FMFumiaki Mukohara
Fumiaki Mukohara
MMMasaki Magari
Masaki Magari
AMAi Miyamoto
Ai Miyamoto
YTYosuke Togashi
Yosuke Togashi
Brain metastasis is a poor prognostic factor in patients with cancer. Despite showing efficacy in many extracranial tumors, immunotherapy with anti–PD-1 mAb or anti–CTLA4 mAb seems to be less effective against intracranial tumors. Promisingly, recent clinical studies have reported that combination therapy with anti–PD-1 and anti–CTLA4 mAbs has a potent antitumor effect on brain metastasis, highlighting the need to elucidate the detailed mechanisms controlling the intracranial tumor microenvironment (TME) to develop effective immunotherapeutic strategies. In this study, we analyzed the tumor-infiltrating lymphocytes in murine models of brain metastasis that responded to anti–CTLA4 and anti–PD-1 mAbs. Activated CD4+ T follicular helper (TFH) cells with high CTLA4 expression characteristically infiltrated the intracranial TME, which were activated by combination anti–CTLA4 and anti–PD-1 treatment. The loss of TFH cells suppressed the additive effect of CTLA4 blockade on anti–PD-1 mAb. B-cell–activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) produced by abundant myeloid cells, particularly CD80hiCD206lo proinflammatory M1-like macrophages, in the intracranial TME induced B-cell and TFH-cell infiltration and activation. Furthermore, the intracranial TME of patients with non–small cell lung cancer featured TFH- and B-cell infiltration as tertiary lymphoid structures. Together, these findings provide insights into the immune cell cross-talk in the intracranial TME that facilitates an additive antitumor effect of CTLA4 blockade with anti–PD-1 treatment, supporting the potential of a combination immunotherapeutic strategy for brain metastases. Significance: B-cell and CD4+ T follicular helper cell activation via BAFF/APRIL from abundant myeloid cells in the intracranial tumor microenvironment enables a combinatorial effect of CTLA4 and PD-1 blockade in brain metastases.